Xue-Ying Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xue-Ying Huang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Tian-Yu Huang
Grade 2016, The First Department of Clinical Medicine, Bengbu Medical College, 2600 Donghai Road, Bengbu 233030, China
3 shared publicationsXiao-Ming Zhang
Department of Anatomy, Anhui Medical University, 81 Meishan Road, Hefei 230032, China
3 shared publicationsYong-Fang Gong
Department of Anatomy, Anhui Medical University, 81 Meishan Road, Hefei 230032, China
3 shared publicationsZhen-Zhen Wang
Department of Anatomy, Anhui Medical University, 81 Meishan Road, Hefei 230032, China
3 shared publicationsFei Liu
Department of Anatomy, Anhui Medical University, Hefei, China
2 shared publications- Xiao-Ming Zhang
Department of Anatomy, Anhui Medical University, 81 Meishan Road, Hefei 230032, China
2 shared publications
Latest Publications
- 1 January 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 90, 107200
Scar-reducing effects of gambogenic acid on skin wounds in rabbit ears
- 1 January 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 90, 107200
Scar-reducing effects of gambogenic acid on skin wounds in rabbit ears
- 1 June 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 83, 106418
Effects of sorafenib on fibroblast-like synoviocyte apoptosis in rats with adjuvant arthritis
- 1 June 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 83, 106418
Effects of sorafenib on fibroblast-like synoviocyte apoptosis in rats with adjuvant arthritis
- Open Access
- 24 December 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 17 (3) , 1663-1669
Insulin‑like growth factor 2 promotes the adipogenesis of hemangioma‑derived stem cells
Infantile hemangioma (IH), which is the most common tumor in infants, is characterized by rapid proliferation followed by spontaneous regression into fibro‑fatty tissue in childhood. However, its specific mechanism has not been clarified. Our previous studies showed that insulin‑like growth factor 2 (IGF‑2) is increased in the proliferative phase of IH, which is deemed to form from hemangioma‑derived stem cells (HemSC). However, it remains unclear whether IGF‑2 can promote the adipogenic differentiation of HemSCs and the signaling mechanisms involved require further elucidation. In the present study, CCK-8 assay was used to detect the effect of different concentrations of IGF-2 on the proliferation of HemSCs. Immunohistochemistry was applied to observe the expression of IGF-2 and its receptors in cells. Oil red o-staining of adipogenesis was conducted after cells recevied no treatment or were induced with IGF-2 or IGF-2 plus OSI-906 for 10 days. Cells were cultured in EGM-2/FBS-10% alone or containing IGF-2, IGF-2 plus OSI-906 or IGF-2 plus LY294002 and the protein expression of C/EBPα, C/EBPβ, PPARγ, adiponectin, p-AKT and total AKT was determined using western blot analysis. In another experiment, cells were treated with 25, 50 or 100 μM propranolol, or vehicle. C/EBPα, C/EBPβ, PPARγ and IGF-2 were analyzed using western blot analysis or reverse transcription-quantitative polymerase chain reaction. Results indicated that IGF‑2 significantly promoted the cell proliferation and lipid accumulation of HemSCs. The expression of phosphorylated AKT (p‑AKT), C/EBPα, C/EBPβ, PPARγ and adiponectin was increased in IGF‑2‑treated HemSCs culture, whereas these changes were repressed by the inhibition of either the IGF‑1 receptor (IGF‑1R) or phosphoinositide 3‑kinase (PI3K). Our previous research showed that propranolol accelerated adipogenesis in HemSCs and induced the upregulation of IGF‑2. The results of the present study indicate that IGF‑2 is able to accelerate adipogenesis, and the propranolol‑induced promotion of dysregulated adipogenesis may be mediated by the IGF‑2 via IGF‑1R and PI3K pathways.
- 24 December 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 17 (3) , 1663-1669
Open AccessInsulin‑like growth factor 2 promotes the adipogenesis of hemangioma‑derived stem cells
Infantile hemangioma (IH), which is the most common tumor in infants, is characterized by rapid proliferation followed by spontaneous regression into fibro‑fatty tissue in childhood. However, its specific mechanism has not been clarified. Our previous studies showed that insulin‑like growth factor 2 (IGF‑2) is increased in the proliferative phase of IH, which is deemed to form from hemangioma‑derived stem cells (HemSC). However, it remains unclear whether IGF‑2 can promote the adipogenic differentiation of HemSCs and the signaling mechanisms involved require further elucidation. In the present study, CCK-8 assay was used to detect the effect of different concentrations of IGF-2 on the proliferation of HemSCs. Immunohistochemistry was applied to observe the expression of IGF-2 and its receptors in cells. Oil red o-staining of adipogenesis was conducted after cells recevied no treatment or were induced with IGF-2 or IGF-2 plus OSI-906 for 10 days. Cells were cultured in EGM-2/FBS-10% alone or containing IGF-2, IGF-2 plus OSI-906 or IGF-2 plus LY294002 and the protein expression of C/EBPα, C/EBPβ, PPARγ, adiponectin, p-AKT and total AKT was determined using western blot analysis. In another experiment, cells were treated with 25, 50 or 100 μM propranolol, or vehicle. C/EBPα, C/EBPβ, PPARγ and IGF-2 were analyzed using western blot analysis or reverse transcription-quantitative polymerase chain reaction. Results indicated that IGF‑2 significantly promoted the cell proliferation and lipid accumulation of HemSCs. The expression of phosphorylated AKT (p‑AKT), C/EBPα, C/EBPβ, PPARγ and adiponectin was increased in IGF‑2‑treated HemSCs culture, whereas these changes were repressed by the inhibition of either the IGF‑1 receptor (IGF‑1R) or phosphoinositide 3‑kinase (PI3K). Our previous research showed that propranolol accelerated adipogenesis in HemSCs and induced the upregulation of IGF‑2. The results of the present study indicate that IGF‑2 is able to accelerate adipogenesis, and the propranolol‑induced promotion of dysregulated adipogenesis may be mediated by the IGF‑2 via IGF‑1R and PI3K pathways.
- 12 May 2018
- Published by Wiley in The Anatomical Record
- Vol. 301 (9) , 1519-1526
Antiarthritic Effects of Sorafenib in Rats with Adjuvant‐Induced Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial membrane of joints. In this study, we aimed to investigate whether sorafenib exerts antiarthritic effects on RA in vivo. Adjuvant arthritis (AA) was induced (day 0) in male Sprague–Dawley rats by intradermal injection of 0.1 mL of complete Freund's complete adjuvant into the left hind paw. Sorafenib (10, 20, or 40 mg/kg/day) was administered intragastrically from day 10 to 24. Body weight, paw volume, synovial inflammation, and tumor necrosis factor alpha (TNF‐α), interleukin‐1β (IL‐1β), IL‐10, and IL‐17 serum levels were detected. In addition, microvascular density (MVD) and the expression of vascular endothelial growth factor receptor 2 (VEGFR‐2) and fibroblast growth factor receptor 1 (FGFR‐1) in synovial tissues were analyzed. Our data revealed that sorafenib administration led to significant body weight gain in AA rats but suppressed paw swelling, synovial hyperplasia, and inflammatory infiltration. Furthermore, it decreased TNF‐α, IL‐1β, and IL‐17 serum levels and upregulated IL‐10. MVD and VEGFR‐2 and FGFR‐1 expression in synovial tissues were significantly reduced. Thus, this study shows that sorafenib exerts anti‐arthritic effects in AA rats and therefore has potential in RA treatment. Anat Rec, 301:1519–1526, 2018.
- 12 May 2018
- Published by Wiley in The Anatomical Record
- Vol. 301 (9) , 1519-1526
Antiarthritic Effects of Sorafenib in Rats with Adjuvant‐Induced Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial membrane of joints. In this study, we aimed to investigate whether sorafenib exerts antiarthritic effects on RA in vivo. Adjuvant arthritis (AA) was induced (day 0) in male Sprague–Dawley rats by intradermal injection of 0.1 mL of complete Freund's complete adjuvant into the left hind paw. Sorafenib (10, 20, or 40 mg/kg/day) was administered intragastrically from day 10 to 24. Body weight, paw volume, synovial inflammation, and tumor necrosis factor alpha (TNF‐α), interleukin‐1β (IL‐1β), IL‐10, and IL‐17 serum levels were detected. In addition, microvascular density (MVD) and the expression of vascular endothelial growth factor receptor 2 (VEGFR‐2) and fibroblast growth factor receptor 1 (FGFR‐1) in synovial tissues were analyzed. Our data revealed that sorafenib administration led to significant body weight gain in AA rats but suppressed paw swelling, synovial hyperplasia, and inflammatory infiltration. Furthermore, it decreased TNF‐α, IL‐1β, and IL‐17 serum levels and upregulated IL‐10. MVD and VEGFR‐2 and FGFR‐1 expression in synovial tissues were significantly reduced. Thus, this study shows that sorafenib exerts anti‐arthritic effects in AA rats and therefore has potential in RA treatment. Anat Rec, 301:1519–1526, 2018.
- 1 July 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 91, 680-686
Effect of recombinant human endostatin on hypertrophic scar fibroblast apoptosis in a rabbit ear model
- 1 July 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 91, 680-686
Effect of recombinant human endostatin on hypertrophic scar fibroblast apoptosis in a rabbit ear model
- 1 November 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 791, 647-654
Inhibitory effect of recombinant human endostatin on the proliferation of hypertrophic scar fibroblasts in a rabbit ear model
- 1 November 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 791, 647-654
Inhibitory effect of recombinant human endostatin on the proliferation of hypertrophic scar fibroblasts in a rabbit ear model
- 13 November 2013
- Published by Elsevier in European Journal of Pharmacology
- Vol. 723, 7-14
Anti-proliferative effect of recombinant human endostatin on synovial fibroblasts in rats with adjuvant arthritis
- 13 November 2013
- Published by Elsevier in European Journal of Pharmacology
- Vol. 723, 7-14
Anti-proliferative effect of recombinant human endostatin on synovial fibroblasts in rats with adjuvant arthritis